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Abstract 
 
Intracellular bacterial pathogens survive and replicate within specialized eukaryotic cell 
organelles.  To establish their intracellular niches these pathogens have adopted sophisticated 
strategies to control intracellular membrane trafficking. Since Rab-family GTPases are 
critical regulators of endocytic and secretory membrane trafficking events, many intracellular 
pathogens have evolved specific mechanisms to modulate or hijack Rab GTPases dynamics 
and trafficking functions. One such strategy is the delivery of bacterial effectors through 
specialized machines to specifically target Rab GTPases. Some of these effectors functionally 
mimic host proteins that regulate the Rab GTP cycle, while others regulate Rabs proteins 
through their post-translation modifications or proteolysis. In this review, we examine how 
the localization and function of Rab-family GTPases are altered during infection with three 
well-studied intracellular bacterial pathogens, Mycobacterium tuberculosis, Salmonella 
enterica and Legionella pneumophila.  We also discuss recent findings about specific 
mechanisms by which these intracellular pathogens target this protein family. 
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Introduction 
 
Intracellular bacterial pathogens are able to survive and replicate in their host cells by 
establishing an intracellular niche. Although many of these pathogens are facultative 
intracellular pathogens, and therefore can replicate both outside and within host cells, it is 
clear that they gain an advantage from living within specialized membranous compartments 
in the cytoplasm of the eukaryotic cell. This advantage often derives from increased access to 
nutrients or avoidance of the immune system. In contrast to non-pathogenic bacteria that are 
internalized and efficiently killed by phagocytic cells, intracellular pathogens survive and 
often replicate after internalization into eukaryotic cells. Upon phagocytosis, non-pathogenic 
bacteria are internalized into a compartment, the early phagosome, which is originated 
through the invagination of the plasma membrane. This compartment undergoes rapid 
maturation and, through a series of membrane trafficking events, matures into a late 
phagosome and finally into a phagolysosome, where the internalized bacteria are destroyed. 1, 
2  As it will be discussed below, bacterial pathogens are able to escape this fate, in most cases 
by subverting the trafficking mechanisms controlling this maturation pathway.  
 
Rab GTPases are the largest group of the Ras superfamily of small GTPases, with more than 
60 members encoded within the human genome.  They regulate different intracellular 
membrane trafficking events, including membrane fission from donor compartments, 
membrane cargo transport along the cytoskeleton, and membrane tethering and fusion to 
acceptor compartments. 3, 4  Many intracellular bacterial pathogens evolved strategies to 
specifically target these proteins to modulate these different trafficking events. In this review 
we will focus on three bacterial pathogens – Mycobacterium tuberculosis, Salmonella 
enterica, Legionella pneumophila – that have been shown to disrupt Rab GTPase localization 
or function by different strategies.  
 
 
Mycobacterium tuberculosis manipulation of the endocytic pathway 
 
The genus Mycobacterium includes many important intracellular bacterial pathogens. 
Mycobacterium tuberculosis (M. tuberculosis) is the cause of tuberculosis, a bacterial air-
borne infection that affects around 9 millions people worldwide. M. tuberculosis is grouped 
with other genetically related bacteria that cause similar disease in other animals, forming the 
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Mycobacterium tuberculosis complex. Alveolar macrophages are among the first cell types 
encountered by these bacteria in the lungs and, therefore, subversion of macrophage function 
is critical for establishment of an infection.  The interaction of M. tuberculosis and the other 
closely related pathogens, including the attenuated strain Mycobacterium bovis (M. bovis) 
BCG, with macrophages has been extensively investigated and no significant difference in 
the ability of the two pathogens to interact with trafficking pathways in these cells has been 
reported. Therefore, we will use the term Mycobacterium in this review to refer without 
distinction to either M. tuberculosis or M. bovis BCG. It is well established that after 
phagocytosis Mycobacterium can survive within macrophages 5, and that intracellular 
survival depends on the pathogen’s ability to inhibit phagosome fusion with lysosomal 
content (Fig. 1). 6, 7  The Rab GTPases Rab5 and Rab7 sequentially control the formation and 
subsequent maturation of the phagosomes into phagolysosomes. 1  It has been shown that 
while Rab5 is detected on the Mycobacterium phagosome, Rab7 is not, suggesting that this 
pathogen blocks the progressions of the phagosome through the canonical phagocytic 
pathway, by blocking the Rab5 to Rab7 step of maturation (also known as Rab5-Rab7 
conversion). 8-10  Consistent with this hypothesis, both mature lysosomal hydrolases and the 
vacuolar ATPase are not detected on the Mycobacterium-containing vacuole. 11, 12  The 
specific mechanisms by which Mycobacterium prevents phagosomal maturation are 
incompletely understood but it is clear that unique lipids of its envelope, such as the 
mannose-capped lipoarabinomannan (man-LAM), play a central role in this process.  It has 
been shown that in contrast to control latex beads, man-LAM coated beads prevent the 
recruitment of the Rab5 effector early endosome antigen-1 (EEA1) and delivery of lysosomal 
enzymes to the phagosome. 9, 13  This block of phagosome maturation was suggested to be 
mediated by an inhibition of the phosphatidylinositol 3-phosphate (PI3P) production by the 
PI3Kinase hVps34. 13  More recently, somehow in contrast with previous findings, it has been 
reported that Mycobacterium does not necessarily inhibit the Rab7 recruitment to the vacuole 
but, rather, it appears to inhibit its function. 14  In fact, it was shown that Rab7 is present in a 
GDP-bound form in Mycobacterium-infected macrophages and that mycobacterial infection 
inhibits the recruitment of the Rab effector, Rab-interacting lysosomal protein (RILP). In 
support of the idea that Rab7 is present but inactive on the mycobacterial phagosome, it has 
been reported that rate of fluorescence recovery for Rab7 on mycobacterial phagosomes is 
lower than that on the phagosomes containing latex beads. 15  More recently, the secreted 
mycobacterial nucleoside diphosphate kinase (Ndk; Table 1) was shown to act in vitro as a 
GTPase activating protein (GAP) for Rab5 and Rab7, suggesting a novel mechanism to 
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prevents recruitment of RILP and EEA1 to the Mycobacterium phagosome. 16  However, the 
absence of Ndk has only a minor effect on the survival of Mycobacterium, suggesting that 
this bacterium may employ additional strategies to prevent phagolysosome maturation.  
 
In addition to Rab7, mycobacteria also interact with other endosomal Rab GTPases.  For 
example, Rab34 is up-regulated in Mycobacterium-infected macrophages 17 and Rab34 
silencing or overexpression results in increased survival or killing of Mycobacterium. 18  
Although the mechanisms by which Rab34 may limit Mycobacterium intracellular survival 
are not known, it is intriguing that RILP is also an effector for this GTPase.  Furthermore, 
siRNA depletion of Rab34 impairs the fusion of phagosomes with late endosomes/lysosomes, 
while Rab34 overexpression promotes phagosomal maturation. 18  
 
Rab10 was also detected on the mycobacterial phagosome at very early time points after 
infection, even before Rab5 recruitment. 19  RNAi-mediated Rab10 knockdown or 
overexpression of Rab10 dominant-negative mutant delayed maturation of phagosomes of 
IgG-opsonized latex beads or heat killed-mycobacteria. Moreover, overexpression of a 
constitutively active mutant of Rab10 partially rescued live-Mycobacterium-containing 
phagosomes maturation.  19  These results suggested that Rab10 acts upstream of Rab5 to 
modulate the phagosome formation and maturation.  It is not clear how Rab10 may modulate 
Mycobacterium intracellular survival.  In response to insulin stimulation, this GTPase 
controls the translocation to the plasma membrane of the GLUT4 glucose receptor.  
However, it is not known if there is a link between this activity and the ability of this GTPase 
to modulate the intracellular replication of Mycobacterium. 
 
Rab14 and Rab22a are also recruited to the mycobacterial phagosome. 20, 21  Disruption of the 
function of Rab14 or Rab22a either by depletion or the expression of dominant negative 
mutants disrupts the maturation of the Mycobacterium-containing phagosome leading to the 
acquisition of lysosomal markers. 20, 21  In this sense, the function of these GTPases appears to 
be opposite to the role of the GTPases discussed above.  However, the specific role of these 
GTPases in the maturation of the Mycobacterium-containing vacuole is not understood.  
 
In conclusion, many Rab GTPases can modulate the ability of mycobacteria to survive in 
macrophages, indicating a complex regulation of the trafficking events underpinning the 
phagocytic process and the phagolysosome formation.  However, the mechanisms underlying 
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the ability of mycobacteria to hijack these Rab GTPases or the specific roles that the different 
Rab GTPases play in the establishment of the Mycobacterium intracellular niche remains 
mostly unknown.  
 
Salmonella enterica interactions with endocytic and secretory Rabs 
 
Salmonella enterica (Salmonella) is an intracellular bacterial pathogen species that comprises 
more than 2,000 serovars.  They cause a variety of illnesses in vertebrate hosts, ranging from 
self-limited intestinal infections to life-threatening diseases. 22  Furthermore, while the 
majority of Salmonella serovars can infect a broad range of hosts (e.g., Salmonella 
Typhimurium), others are extremely host-adapated (e.g., Salmonella Typhi). 18  Despite their 
different pathogenic behaviour and host range, all the Salmonella serovars share a core set of 
virulence factors that allow them to enter and replicate within host cells.  These properties are 
strictly dependent on the delivery of a set of bacterial effectors through two type III secretion 
systems (TTSS) encoded within their pathogenicity islands 1 (SPI-1) and 2 (SPI-2). 23, 24 
 
Several studies have shown a close interaction between Salmonella and Rab-family GTPases.  
Immediately after Salmonella internalization, the Salmonella-containing vacuole (SCV) 
interacts with early endosomes and acquires Rab4, Rab5 and the Rab5 effector EEA1 (Fig. 
2A). 25, 26  Rab5 recruitment to the SCV and its retention are modulated by the SPI-1 TTSS 
effector protein SopB, which through its a phosphatidylinositide phosphatase activity 
modulates the phosphoinositide composition of the SCV. 27-31  Specifically, how the 
phosphoinositide composition of the SCV affects the retention of Rab5 is not understood.   
 
Within 1 hour from bacterial internalization, the SCV recruits Rab7, and with it the Rab7 
effector RILP and the lysosomal glycoproteins, such as LAMP-1 and LAMP-2. 25, 32, 33  The 
SCV also acquires the vacuolar proton pump V-ATPase responsible for the acidification of 
this compartment. 25  Rab7 function is essential for the vacuolar acquisition of the lysosomal 
glycoprotein LAMP-1 and for Salmonella replication in epithelial cells, since its depletion or 
the expression of dominant-negative forms of this GTPase result in significant reduction in 
intracellular bacterial replication. 33, 34  It has been shown that late endosomal/lysosomal 
content is transferred to the SCVs, early (30 min) after infection and continues for several 
hours, in a process that requires Rab7 and results in the acidification of the SCV. 35  
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Therefore, in contrast to mycobacteria that replicates in an intracellular compartment devoid 
of lysosomal markers, Salmonella replicates in an intracellular niche that acquires many 
features of a lysosome, including acidic pH. Indeed, acidification of the vacuolar 
environment is essential for Salmonella survival and replication 36, because it is thought to be 
a very important cue for the induction of the SPI-2 T3SS, which is critical for Salmonella 
survival and replication. 37, 38  Although sharing many features with a lysosome, the SCV is 
still devoid of many properties characteristic of this compartment. For example, it never 
acquires the mannose-6-phosphate receptor (MPR) and enzymes that are transported to 
lysosomes in an MPR-dependent manner, such as cathepsin D. 39, 40  It has been shown that 
the SPI-2 T3SS effector SifA interferes with the Rab9-mediated delivery of MPR to the SCV 
by sequestering this Rab GTPase in a complex with kinesin-interacting protein (SKIP). 41  
 
Recent work on the human-restricted pathogen S. Typhi has uncovered the existence of other 
Rab-dependent pathways leading from a post-Golgi compartment to the SCV. The Rab 
GTPases Rab32, Rab38 and Rab29, also known as Rab7L1, are recruited to the S. Typhi-
containing vacuole, but not to the S. Typhimurium-containing vacuole (Fig. 2B). 34, 42  All 
these three phylogenetically related Rabs localize on the Golgi or post-Golgi compartments. 
34, 43, 44  Rab32 and Rab38 are known to be required for the post-Golgi trafficking of 
melanocytic enzymes to maturing melanosomes in pigment cells and specialized cargo to 
maturing dense granules in platelets. 43, 45  Rab29, which is associated with risk of Parkinson’s 
disease, is involved in post-Golgi trafficking events that lead to neuronal development 46, 47 
and is required for the transport of typhoid toxin from the S. Typhi vacuoles to the plasma 
membrane. 34  The absence of Rab32, Rab38 and Rab29 from the S. Typhimurium-containing 
vacuole is due to the activity of the T3SS effector protein GtgE, which is not present in the 
genome of S. Typhi and Salmonella Paratyphi, another human-restricted Salmonella. GtgE, 
which belongs to the clan CA superfamily of cysteine proteases, is a specific protease for 
these three Rab GTPases. 42, 48, 49   Remarkably, expression of GtgE in S. Typhi allowed this 
human-specific pathogen to overcome host-restriction and replicate in mouse tissues. 42   
Further dissection of this phenotype indicated that Rab32 is the relevant target for GtgE to 
overcome this host restriction mechanism since removal of this GTPase or its guanine 
nucleotide exchange factor BLOC-3 50 allowed S. Typhi survival in mouse macrophages and 
replication in mouse tissues. 42  These studies therefore identified a novel Rab32-dependent 
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pathogen restriction pathway that prevents the replication of the human-adapted S. Typhi and 
S. Paratyphi in non-human hosts.  
 
The importance of this novel cell-intrinsic pathogen-restriction pathway is highlighted by the 
finding that S. Typhimurium targets this pathway in a functionally redundant manner. Indeed, 
in addition to GtgE, Rab32 is targeted by the T3SS effector protein SopD2. 51  This effector is 
widely distributed across Salmonella serovars but it is a pseudogene in the human-adapted S. 
Typhi and Salmonella Paratyphi serovars.  SopD2 exerts its inhibitory function of Rab32 by 
acting as a GAP and stimulates Rab32 intrinsic GTPase activity. 51  SopD2 GAP activity 
results in the Rab32 displacement from the surface of the vacuole. 51  Although deletion of 
either GtgE or SopD2 does not eliminate the ability of S. Typhimurium to prevent Rab32 
recruitment to the its vacuole, removal of both effectors results in efficient Rab32 
recruitment.  A S. Typhimurium strain defective for both SopD2 and GtgE is drastically 
impaired for its ability to cause a systemic infection in mouse. 51   However, this mutant strain 
is as virulent as a wild-type strain in Rab32- or BLOC-3-deficient mice.  This indicates that 
Salmonella evolved redundant strategies to neutralize a critical Rab32-dependent host-
defense pathway and establish a systemic infection.  In melanocytes and in platelets Rab32 is 
involved in a pathway that delivers specialized cargo from post-Golgi compartments to 
maturing lysosomal-related organelles. 45, 52   The role of Rab32 in post-Golgi trafficking 
suggests that in macrophages, and possibly in other cell types dedicated to host-defense, 
Rab32 controls a trafficking pathway delivering specialized molecules that can kill S. Typhi 
or other intracellular pathogens unable to neutralize this host-defense pathway. 42, 53, 54  
Interestingly, Rab32 appears to have quite an opposite role in the intracellular growth of L. 
pneumophila, an intracellular bacterial pathogen that, as discussed below, hijacks the early 
secretory pathway to establish a replicative vacuole. Indeed, Rab32 is required for efficient L. 
pneumophila replication in lung carcinoma epithelial cells. 55 These observations highlight 
the substantial difference of survival strategies implemented by different bacterial pathogens.  
 
It has been suggested that SopD2 may have an additional activity that allows it to interfere 
with Rab7 function.  Indeed, it has been shown that SopD2 blocks endocytic traffic to 
lysosomes by binding Rab7 and acting as an inhibitor of the Rab7 guanine nucleotide 
exchange reaction through a poorly understood mechanism. 56   It has been reported that this 
inhibitory activity is dependent on its N-terminal domain, indicating that, whatever its 
mechanism, this inhibitory function must be independent of its GAP activity, which requires 
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an arginine in the C-terminal end of the protein.  Therefore, SopD2 seems to have evolved 
two functions to facilitate Salmonella survival in an intracellular compartment.  One to 
prevent Rab7-mediated lysosomal fusion, and the other to neutralize an antimicrobial Rab32-
dependent trafficking pathway.  
 
In addition to Rab32, Rab38 and Rab29, other Rabs GTPases appear to also be excluded from 
the SCV.  For example, Rab8B, Rab13, Rab23, Rab35 are enriched on model phagosomes, 
but are absent from the S. Typhimurium-containing vacuole. 57  Exclusion of these Rabs from 
the SCV appears to be dependent on the SPI-1 TTSS effector SopB. 31  In fact, a S. 
Typhimurium ∆sopB mutant shows recruitment of these four Rabs on its SCV.  It has been 
reported that the phosphoinositide phosphatase SopB prevents the localization of these 4 Rab 
GTPases by reducing the level of negative charged lipids on the surface of SCV. 31  In 
conclusion, Salmonella has evolved multiple mechanisms to modulate or antagonize Rab 
GTPase function to create a compartment where this pathogen can survive and replicate. 
 
Legionella pneumophila subversion of secretory Rabs 
 
Legionella pneumophila (L. pneumophila) uses multiple complex strategies to interact with 
Rab GTPases.  The natural hosts of L. pneumophila are fresh water amoebas and it is 
believed that this bacterium only occasionally causes human infections as the result of 
inhalation of aerosolized water droplets contaminated with L. pneumophila.  It is thought that 
through extensive co-evolution with its natural host, L. pneumophila has evolved very 
sophisticated and most often redundant mechanisms to survive and replicate within the 
intracellular environment of the amoeba. The conservation of many basic cellular biological 
processes dictates that many of the strategies evolved by L. pneumophila to thrive in its 
natural unicellular host also allow it to replicate within human macrophages (reviewed in 58).  
Once internalized by human macrophages, L. pneumophila resides within a specialized 
compartment known as the Legionella-containing vacuole (LCV). The LCV does not follow 
the classical phagocytic maturation route and therefore does not fuse with lysosomes (Fig. 3). 
Rather, through the activity of multiple effector proteins of a type IV protein secretion system 
(T4SS), Legionella modulates membrane trafficking to build a specific phagosomal 
compartment (reviewed in 59-61 ).  The LCV does not acquire Rab5 or Rab7 indicating that it 
deviates from the canonical endocytic pathway pretty early after its formation.  The 
mechanism by which L. pneumophila targets the early endocytic machinery are not known 
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but it has been suggested that the effector protein VipD may contribute to this activity by 
binding Rab5 and Rab22, thus preventing their interaction with their downstream effectors 
Rabaptin-5 and EEA1. 62 Recently, another L. pneumophila T4SS effector, Lgp0393, was 
reported to target Rab5, as well as Rab21 and Rab22. 63  Lgp0393 is remotely related to the 
Rab5 guanine nucleotide exchange factor Rabex-5 and has a low guanine nucleotide 
exchange factor activity on Rab5, Rab21 and Rab22. The functional role of the interaction of 
Lgp0393 with endosomal Rab GTPases and this enzymatic activity still remain to be 
clarified. 
 
Remarkably, at least 6 of the L. pneumophila T4SS effectors target the Rab GTPases Rab1 
(reviewed in 59).  Rab1, a critical regulator of trafficking between ER and the Golgi complex, 
is recruited to the Legionella-containing vacuole within the first hour of infection. 64, 65  An 
effector called DrrA or SidM acts as a guanine exchange factor (GEF) for this GTPase, 
resulting in tethering and fusion of endoplasmic reticulum derived vesicles to the LCV. 66, 67  
DrrA has a PI4P binding domain that mediates its interaction with the membrane 68  and a 
GEF domain with high affinity for the GDP-bound form of Rab1. 69-71  Because of its high 
affinity for the GDP-bound form of Rab1 DrrA function both as a GEF and a Rab-guanine 
nucleotide displacement inhibitor (RabGDI) displacement factor.  In addition, the amino-
terminal region of DrrA act as a nucleotidyl transferase that covalently attaches an AMP 
moiety onto a conserved tyrosine residue of Rab1 using ATP as a substrate, a reaction known 
as AMPylation. 72, 73  In addition, to DrrA, L. pneumophila has evolved other effectors that 
modify Rab1 to stabilize it on the LCV and preventing its inactivation, indicating that 
controlling Rab1 activity is critical for L. pneumophila intracellular survival and replication.  
Another L. pneumophila effector, called AnkX, also modifies Rab1 through the addition of a 
phosphocholine (PC) moiety to a serine residue using CDP-choline as substrate, a reaction 
called phosphocholination. 74, 75  Both the tyrosine residue AMPylated by DrrA and the serine 
residue phosphocholinated by AnkX are located within the switch II loop of Rab1, and, 
consequently, the modified Rab1 protein has reduced affinity for GAPs and effectors. 72, 74  
Remarkably, the AMPylation and phosphocholination modification on Rab1 are reversed by 
the concerted action of the type IV effector proteins SidD and Lem3, which respectively 
deAMPylate and dephosphocholinate Rab1 (reviewed in  76). The deAMPylase reaction is 
performed by the effector protein SidD, an enzyme with structural similarity to metal-
dependent protein phosphatases. 76-80  The activity of Rab1 is also regulated by the type IV 
effector protein LepB, a Rab GAP that is found associated to the LCV only later during 
 11
infection, when the LCV has acquired endoplasmic reticulum features. 81  Therefore, Rab1 
activity appears to be tightly controlled, likely to ensure the proper spatial and temporal 
activation of Rab1 in the L. pneumophila-infected cell to facilitate the proper sculpting of the 
LCV and its removal from the endo-lysosomal pathway. In addition to Rab1, some of the 
effectors described above can also target other Rab GTPases although the functional 
consequences of these interactions are unclear. 74, 82 
 
L. pneumophila also targets Rab GTPases through ubiquitination mediated by a family of L. 
pneumophila effectors that use a novel mechanism of ubiquitination that does not require E2 
or E3 ligases. 83  This family of effectors, which includes SidE, SdeA, SdeB, and SdeC, 
contains an aminoacid motif (R-S-ExE) found in mono-ADP ribosyltransferases. 83  This 
enzymatic domain mediates the ubiquitination of Rab33b, Rab1 and, to a lesser extent, other 
Rab GTPases associated with the endoplasmic reticulum and the Golgi complex, through a 
complex and unprecedented biochemical pathway, which involves the formation of a AMP-
ubiquitin adduct and atypical direct transfer of ubiquitin. 83  Remarkably, Rab GTPases 
involved in pathogen internalization, such as Rab5, do not appear to be targets of this novel 
mechanism of ubiquitination.  In summary, through mechanisms presumably evolved in the 
context of interaction with its natural unicellular host, L. pneumophila has adopted multiple 
mechanisms to modulate Rab GTPase function in macrophages and thus facilitate its 
intracellular survival and replication. 
 
 
Conclusions 
 
Intracellular bacterial pathogens have evolved multiple, often redundant mechanisms to target 
Rab GTPase proteins to modulate or antagonize their multiple and diverse functions.  
Remarkably, the three bacterial pathogens discussed in this review, Mycobacterium 
tuberculosis, Salmonella enterica, and Legionella pneumophila, display unique trafficking 
subversion strategies to avoid intracellular killing. The study of these mechanisms has not 
only generated very important understanding of pathogenic mechanisms but has also 
provided truly unique insight into Rab GTPase function.  Furthermore, some of these studies 
have revealed novel post-translational modifications of key regulatory proteins thus opening 
new vistas into eukaryotic regulatory mechanism.  Remarkable as these discoveries have 
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been, the fact remains that most of the activities of bacterial effector proteins are unknown, a 
clear indication that the best is yet to come.  
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Figure legends 
 
Figure 1.  Trafficking model of the Mycobacterium-containing vacuole. After phagocytosis the 
Mycobacterium-containing vacuole acquires early-phagocytic features and Rab GTPases (green 
circles). However, it does not interact with the late endocytic pathway and does not acquire lysosomal 
markers, such as lysosomal hydrolases, the vATPase and lysosomal glycoproteins. 
 
Figure 2.  Trafficking model of the Salmonella-containing vacuole.  (A) After phagocytosis the 
Salmonella-containing vacuole (SCV) acquires first early-endocytic features and later most of the 
lysosomal features. It also acquires sequentially early endocytic Rab GTPases and Rab7 (green 
circles). However, lysosomal hydrolases are not delivered to the SCV due to a SifA-mediated block of 
Rab9- and MPR-dependent transport pathway. Broad-host range Salmonella serovars, such as S. 
Typhimurium, target Rab32 and related Rab GTPases through GtgE and SopD2 and consequently 
inhibit the delivery of lysosome-related organelle (LRO) enzymes and antimicrobial factors to the 
LRO and SCV.  (B) In contrast to the majority of other Salmonella serovars, the human-adapted S. 
Typhi does not deliver GtgE and SopD2 and, consequently, succumbs to the Rab32-dependent 
antimicrobial pathway in mice. 
 
Figure 3.  Trafficking model of the Legionella-containing vacuole.  After phagocytosis the 
Legionella-containing vacuole (LCV) does not interact with the endocytic pathway and does not 
acquire any of endocytic Rab GTPases (green circles). However, it acquires the secretory Rab, Rab1, 
which is regulated and post-translationally modified by the Legionella T4SS effectors, DrrA, AnkX, 
SidD, Lem3, LepB and SidE. 
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Table 1. Bacterial virulence factors, their biochemical activities, targets and effects on 
Rab GTPase function. 
 
Viruence factor Activity Targets Modulation 
of Rab 
function 
Refs 
Mycobacterium sp.     
Ndk GAP Rab5, Rab7 Deactivation 16  
Salmonella 
enterica 
    
SopB Phosphatidylinositide 
phosphatase 
Phosphoinositides, 
Rho-family 
GTPases 
Indirect 28-31
SifA Binds SKIP, 
sequesters Rab9 
SKIP Rab9 
sequestration 
41, 84
GtgE Protease Rab29, Rab32, 
Rab38 
Removal 34, 42  
SopD2 Rab GAP 
 
 
Inhibitor of GEF 
activity 
Rab32, Rab38 
 
 
Rab7 
Deactivation 
 
 
Deactivation 
51  
 
 
56 
Legionella 
pneumophila 
   56  
VipD Phospholipase A1 Rab5, Rab22 None 62
Lgp0393 GEF Rab5, Rab21, 
Rab22
Unknown 63
DrrA or SidM GEF, RabGDI Rab1 Recruitment to 
the LCV 
66-71
DrrA or SidM Nucleotidyltransferase 
(AMPylation) 
Rab1 Modulation of 
Rab1 
recruitment to 
the LCV 
72,73
 19
AnkX Phosphocholination Rab1 Modulation of 
Rab1 
recruitment to 
the LCV 
74,75
SidD DeAMPylation Rab1 Modulation of 
Rab1 
recruitment to 
the LCV 
76-80
Lem3 Dephosphocholination Rab1 Modulation of 
Rab1 
recruitment to 
the LCV 
76
LepB Rab GAP Rab1 Deactivation 81
SidE and SidE 
family effectors 
NAD-dependent 
ubiquitination 
Rab1, Rab33b  Unknown 83
 
 



